Abstract Library

#4658 The nutritional status worsens over 5 years in patients with gastroenteropancreatic neuroendocrine tumours on treatment with somatostatin analogues

Introduction: Malnutrition is common in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) treated with monthly somatostatin analogues (SSAs). Ideally all malnourished patients are offered nutritional support. However, clinical guidelines and data on the development and progression of malnutrition is lacking.

Conference:

Presenting Author: Clement D

Authors: Soran V, Srirajaskanthan R, Cananea E, Martin W, Minott S,

Keywords: gastroenteropancreatic neuroendocrine tumour, malnutrition, somatostatin analogue,

#4644 First results of peptide-receptor radionuclide therapy in the Russian population of patients with neuroendocrine neoplasms

Introduction: Peptide-receptor radionuclide therapy (PRRT) has demonstrated its efficacy and safety in a number of clinical trials and has become widely used in the treatment of patients with neuroendocrine neoplasms (NEN) expressing somatostatin receptors.

Conference:

Presenting Author: Baranova O

Authors: Baranova O, Geliashvili T, Markovich A, Zhulikov Y, Evdokimova E,

Keywords: NET, PRRT, 177Lu-DOTATATE,

#4634 Management of hypercalcaemia of malignancy in neuroendocrine tumour patients – A case series

Introduction: Hypercalcaemia of malignancy (HM) rarely coexists with neuroendocrine tumours (NET). There are no precise guidelines for management of hypercalcaemia in NET.

Conference:

Presenting Author:

Authors: Klepinowska M, Sagan K, Brzeska A, Andrysiak-Mamos E, Kiedrowicz B,

Keywords: hypercalcaemia of malignancy, neuroendocrine tumour, pancreatic neuroendocrine tumour, hypercalcaemia,

#4611 Management strategies and outcomes for type 1 gastric neuroendocrine tumours measuring > 1cm in diameter

Introduction: Although type 1 gastric neuroendocrine tumours (T1-gNETs) are usually considered indolent diseases, the management and the outcome of tumours >1cm remain not well established.

Conference:

Presenting Author:

Authors: Dell' Unto E, Srirajaskanthan R, Saini A, Salin G, de Mestier L,

Keywords: gastric neuroendocrine tumour, gastric carcinoid, endoscopic treatment,

#4596 Gender and metastatic burden as preoperative predictors of disease progression in patients undergoing surgery for pancreatic neuroendocrine tumours with liver metastases

Introduction: Pancreatic neuroendocrine tumour liver metastases (PanNET LM) are traditionally classified into three types based on their distribution. Surgery is generally considered for patients with type I/II LM, while those with type III LM are typically regarded as unresectable. However, type III PanNET LM encompass a wide range of clinical scenarios, some of which may allow surgical resection in selected cases.

Conference:

Presenting Author: Andreasi V

Authors: Andreasi V, Partelli S, Battistella A, Muffatti F, Tamburrino D,

Keywords: Pan NET, neuroendocrine, liver metastasis, surgery, gender, progression,